Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
Journal: The New England journal of medicine
Published: April 08, 2026
Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia.
Journal: Emerging infectious diseases
Published: May 29, 2025
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
Journal: The Journal of infectious diseases
Published: September 23, 2022
Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.
Journal: Pediatrics
Published: July 20, 2022
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.
Journal: American journal of respiratory and critical care medicine
Published: March 15, 2022
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Journal: The New England journal of medicine
Published: December 15, 2021
Generation of recombinant hyperimmune globulins from diverse B-cell repertoires.
Journal: Nature biotechnology
Published: October 15, 2020
Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
Journal: Human vaccines & immunotherapeutics
Published: March 27, 2020
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
Journal: The Lancet. Infectious diseases
Published: December 20, 2019
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study.
Journal: Vaccine
Published: December 05, 2019
Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.
Journal: The Pediatric infectious disease journal
Published: November 06, 2018
Last Updated: 09/26/2026